CT26 is an N-nitroso-N-methylurethane-(NNMU) induced, undifferentiated colon carcinoma cell line. It was cloned to generate the cell line designated CT26.WT (ATCC CRL-2638). Use CT26.WT mouse fibroblasts with CT26.CL25 (ATCC CRL-2639) as a model for testing immunotherapy protocols and in studies on the host immune response.

2016年2月1日 · The CT26 model is highly responsive to anti-CTLA4 antibody treatment with 100% of treated mice showing tumor regressions.

Establishment of mouse colonic carcinoma cell lines with different metastatic properties.

Active immunotherapy of cancer with a nonreplicating recombinant fowlpox virus encoding a model tumor-associated antigen. Highly metastatic variant of a mouse colon carcinoma cell line, LM17 and its response to GM-CSF gene therapy. Immunomic, genomic and transcriptomic characterization of CT26 colorectal carcinoma.

CT26.CL25 is a cell line exhibiting fibroblast-like morphology that was isolated from the large intestine of a mouse with undifferentiated colon carcinoma. This cell line was deposited by N Restifo and can be used in cancer research.

ct26细胞是以n-亚硝基-n-甲基氨基甲酸酯(nnmu)诱导形成的未分化结肠癌细胞株，它克隆形成的细胞株命名为ct26.wt。用包含编码典型肿瘤相关抗原(taa)β-半乳糖苷酶(β-gal)的lacz基因的逆转录病毒载体lxsn稳定转染ct26.wt细胞，得到致死的亚克隆ct26.cl25。

2021年11月13日 · We performed in vivo screening for anti-PD-1 therapy across 23 syngeneic tumor models and found that CT-26 and Colon 26, which are murine colorectal carcinoma derived from BALB/c mice, showed different sensitivity to anti-PD-1.

In a syngeneic CT26 model, cancer cells from a particular mouse strain are implanted back into mice of the same strain, allowing researchers to study the interaction between the tumor and the immune system in a genetically matched system.

Here, we present an integrated map of the genome, transcriptome and immunome of an epithelial mouse tumor, the CT26 colon carcinoma cell line. We found that Kras is homozygously mutated at p.G12D, Apc and Tp53 are not mutated, and Cdkn2a is homozygously deleted.

2021年11月13日 · Results: We performed in vivo screening for anti-PD-1 therapy across 23 syngeneic tumor models and found that CT-26 and Colon 26, which are murine colorectal carcinoma derived from BALB/c mice, showed different sensitivity to anti-PD-1.